痛風（Gout）治療市場：市場機会分析と予測（～2018）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 13
1.2 List of Figures 15
2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 17
2.3 Upcoming Related Reports 17
3 Disease Overview 18
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 21
3.2 Symptoms 22
3.3 Risk Factors 23
3.4 Prognosis 23
3.5 Quality of Life 24
4 Epidemiology 25
4.1 Risk Factors and Comorbidities 25
4.2 Global Trends 27
4.2.1 US 29
4.2.2 5EU 29
4.3 Forecast Methodology 30
4.3.1 Sources Used 34
4.3.2 Sources Not Used 38
4.3.3 Forecast Assumptions and Methods 40
4.4 Epidemiological Forecast for Gout (2013-2023) 47
4.4.1 Diagnosed Incidence 47
4.4.2 Diagnosed Prevalence 53
4.5 Discussion 61
4.5.1 Epidemiological Forecast Insight 61
4.5.2 Limitations of the Analysis 62
4.5.3 Strengths of the Analysis 63
5 Current Treatment Options 64
5.1 Overview 64
5.2 Product Profiles 67
5.2.1 Anti-Inflammatory Therapies 67
5.2.2 Urate-Lowering Therapies 86
6 Unmet Needs Assessment and Oppportunity Analysis 103
6.1 Overview 103
6.2 Physician and Patient Awareness of Gout 104
6.2.1 Unmet Needs 104
6.2.2 Gap Analysis 105
6.2.3 Opportunity 106
6.3 Noncompliance to Gout Therapies 106
6.3.1 Unmet Needs 106
6.3.2 Gap Analysis 107
6.3.3 Opportunity 107
6.4 Earlier and More Accurate Diagnosis of Gout 107
6.4.1 Unmet Needs 107
6.4.2 Gap Analysis and Opportunity 108
6.4.3 Opportunity 109
6.5 Efficacious and Safe Treatment of Difficult-to-Treat Gout 109
6.5.1 Unmet Needs 109
6.5.2 Gap Analysis and Opportunity 109
6.5.3 Opportunity 110
7 Research and Development Strategies 111
7.1 Overview 111
7.1.1 Targeting Patients with Refractory Gout – Novel Uricosuric Drugs as Add-On Therapy 111
7.1.2 Targeting Patients with Refractory Gout – PEGylation of Uricase 112
7.1.3 Small Molecules as Inhibitors of the Interleukin-1 Beta Pathway 113
7.1.4 Acquisitions and Licensing 113
7.2 Clinical Trial Design 115
7.2.1 Current Clinical Trial Design 115
7.2.2 Future Clinical Trial Designs 120
8 Pipeline Assessment 122
8.1 Overview 122
8.2 Promising Drugs in Clinical Development 124
8.2.1 Lesinurad (RDEA-594) 125
8.2.2 Ulodesine (BCX4208) 130
8.3 Innovative Early-Stage Approaches 134
9 Pipeline Valuation Analysis 138
9.1 Clinical Benchmark of Key Pipeline Drugs 138
9.2 Commercial Benchmark of Key Pipeline Drugs 140
9.3 Competitive Assessment 141
9.4 Top-Line Five-Year Forecast 144
9.4.1 US 147
9.4.2 5EU 148
10 Appendix 150
10.1 Bibliography 150
10.2 Abbreviations 164
10.3 Methodology 168
10.4 Forecasting Methodology 168
10.4.1 Diagnosed Gout Patients 168
10.4.2 Percent Drug-Treated Patients 169
10.4.3 Drugs Included in Each Therapeutic Class 169
10.4.4 Launch and Patent Expiry Dates 169
10.4.5 General Pricing Assumptions 170
10.4.6 Individual Drug Assumptions 171
10.4.7 Pricing of Pipeline Agents 175
10.5 Physicians and Specialists Included in this Study 176
10.6 About the Authors 178
10.6.1 Analyst 178
10.6.2 Therapy Director – CVMD and Infectious Disease 178
10.6.3 Epidemiologist 179
10.6.4 Global Head of Healthcare 179
10.7 About GlobalData 180
10.8 Disclaimer 180